X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR) is expected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $1.07 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

X4 Pharmaceuticals Price Performance

Shares of XFOR opened at $0.31 on Tuesday. X4 Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $1.60. The stock’s 50 day moving average is $0.48 and its two-hundred day moving average is $0.54. The firm has a market capitalization of $53.50 million, a PE ratio of -3.49 and a beta of 0.39. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

Insider Transactions at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 in the last quarter. 1.62% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE raised its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 133,502 shares of the company’s stock after acquiring an additional 22,485 shares during the period. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent reporting period. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.